Arteriocyte announces Launch of Compass Biomedical
CLEVELAND, June 3, 2013 /PRNewswire/ — Arteriocyte, Inc., a leading biotechnology company that is focused on developing and enabling commercial stem cell based therapies announced the launch of Compass Biomedical, the commercial tools division of Arteriocyte that supplies novel cell culturing products and technologies for translational research. As part of the Arteriocyte family, Compass Biomedical has access to the pipeline of cutting edge research from Arteriocyte’s research and development team, as well as collaboration partnerships with leading research institutions making Compass Biomedical an ideal choice to help accelerate the transition from basic research to clinical application. Compass Biomedical already supplies 3 product lines: 1) NANEX(TM) Cell Culture and Expansion Kit; 2) Adhere-34(TM) Cell Culture and Expansion Bag; and 3) PLUS(TM) Cell Culture Supplement.
Compass Biomedical’s core products are based upon the NANEX(TM) biofunctional nanofiber-based technology, that was designed to partially mimic key features of human bone marrow enabling rapid ex vivo cell growth and expansion while maintaining the stem cell’s properties. It is an ideal solution for rapidly culturing hematopoietic stem and progenitor cells (HSC/HPCs) for basic research, therapeutics, drug discovery, and screening. These expanded cells have been used to grow new blood cells (including red blood cells and platelets) and new blood vessels. One of the major challenges in cellular therapy research is the limited number of stem cells present in adult human tissues, which today limits the research and clinical applications of stem cell technology. The NANEX(TM) Cell Culture and Expansion Kit has been designed specifically for the ex vivo expansion of human bone marrow, peripheral blood, and umbilical cord blood derived HSCs/HPCs.
Adhere-34(TM) incorporates the NANEX(TM) nanofiber technology into a fully closed system, enabling sterile and convenient stem cell culturing and rapid expansion for a variety of applications. Adhere-34(TM) will enable researchers to seamlessly transition from the Research Use Only NANEX(TM) Cell Culture and Expansion Kit (in multi-well plate form) to the closed culture ADHERE-34(TM) system, which was developed specifically for use in clinical protocols.
PLUS(TM) Cell Culture Supplement is a cytokine rich replacement for fetal bovine serum (FBS). PLUS(TM) is derived from human platelet lysate and is made using state of the art manufacturing techniques. PLUS(TM) provides a safe, xeno-free serology tested product that minimizes sample variation. PLUS(TM) Cell Culture Supplement has been shown to enhance growth rates of mesenchymal stem cells (MSC) while maintaining key MSC phenotypes when compared to fetal bovine serum.
Arteriocyte Inc., is a leading Biotechnology Company developing and enabling commercial stem cell therapies for human clinical application.
Contact: Ahalya Selvaraj (216) 456-9651 – firstname.lastname@example.org
SOURCE Arteriocyte, Inc.